Glen Rock, NJ — November 20, 2025 — Leads & Copy — RespireRx Pharmaceuticals Inc. has released an open letter providing a progress and status report to its stockholders, stakeholders, strategic partners, and other interested parties.
The letter outlines the challenges faced by the RespireRx Group, which includes subsidiaries EndeavourRx LLC and ResolutionRx Ltd, as well as the strategies implemented to address these challenges. It also highlights the company’s accomplishments in 2025 and its goals for 2026.
ResolutionRx Ltd, a wholly-owned, unlisted public company in Australia, was created in 2023 to develop compounds targeting the endocannabinoid system, particularly dronabinol, for treating obstructive sleep apnea (OSA). A key purpose of ResolutionRx’s creation was to leverage the Australian research and development tax incentive, offering a 43.5% refund on qualified R&D expenditures.
ResolutionRx has secured a finance facility backed by these tax credits to fund a significant portion of its qualified expenditures. The company is also in advanced discussions with an investor for potential equity or equity-linked financing, covering up to 15% of the R&D budget for Australian vendors approved by the investor. A commitment to list ResolutionRx on the Australian Stock Exchange (ASX) is inherent in this financing, with plans to also list on exchanges outside Australia, including the United States.
EndeavourRx LLC, formed on January 27, 2025, focuses on developing AMPAkines and GABAkines, which are positive allosteric neuromodulators (PAMs) designed to enhance the actions of glutamate and GABA on AMPA glutamate and GABA-A receptors, respectively.
A $1.8 million award from the U.S. Department of Defense has been granted to the Shirley Ryan AbilityLab (SRAL) for Phase 2A and 2B human clinical trials using RespireRx’s AMPAkine CX1739 on spinal cord injury patients. Dr. Sandhu at SRAL will conduct the trials to assess the safety and efficacy of CX1739 in improving bladder function, with RespireRx responsible for manufacturing and formulating the clinical material.
In addition, a grant application has been submitted to the U.S. National Institutes of Health for a Phase 2B clinical trial of CX1739 in treating Attention Deficit Hyperactivity Disorder (ADHD). The planned study will be a double-blind, placebo-controlled trial to confirm earlier findings and establish the efficacy of CX717 in a larger patient population.
RespireRx received a $1,499,869 Notice of Award from the NIH’s National Institute of Neurological Disorders and Stroke (NINDS) under the Small Business Innovation Research (SBIR) program to support preclinical toxicology studies for its lead GABAkine, KRM-II-81, for treating epilepsy. Under an Amended and Restated Patent License Agreement with the University of Wisconsin-Milwaukee (UWM) Research Foundation, RespireRx has in-licensed rights to certain selectively acting GABAkines developed at UWM. EndeavourRx LLC will focus on developing KRM-II-81 for epilepsy and pain treatment.
The UWM Research Foundation and RespireRx Pharmaceuticals have amended and restated their patent license agreement to better align with current commercialization strategies. Key updates include updates on regulatory milestone-based payments, revising royalty structures, and adjustment of amounts and timing of patent cost reimbursements.
RespireRx has commenced a Regulation D, Rule 506(c) exempt offering of securities, across the three entities of the RespireRx Group, RespireRx, EndeavourRx and ResolutionRx, with a targeted raise of up to $45 million. Castle Placement, LLC is the exclusive Placement Agent.
ResolutionRx (Australia) will allocate $15 million to advance a proprietary dronabinol formulation for obstructive sleep apnea (OSA). EndeavourRx LLC (Delaware) will allocate $25 million to developing AMPAkines (CX1739 and CX717) for spinal cord injury and ADHD, supported by a U.S. Department of Defense grant and pending NIH funding, and GABAkines (KRM-II-81) for treatment-resistant epilepsy and non-opioid pain. RespireRx Pharmaceuticals Inc. (Delaware parent) will allocate $5 million to support corporate operations, governance, and intellectual property management across the RespireRx Group.
On November 13, 2025, the Securities and Exchange Commission (“Commission”), in Administrative Proceeding File No. 3-22541, in Release No. 104178 issued an Order Making Findings and Revoking Registration of Securities Pursuant to Section 12(j) of the Securities Exchange Act of 1934.
RSPI made the offer of settlement on September 30, 2025. Between September 30, 2025 and the date of the release, RSPI was awaiting determination as to whether its Offer would be accepted.
At this time, the Company plans to register it common stock, and possibly other classes of its stock on Form 10 in the future.
RespireRx intends to complete a definitive agreement with SRAL, maintain, expand, and enhance its intellectual property portfolio, and activate or replace its IND for CX717, pending adequate finance.
Jeff Margolis, Senior Vice President, Chief Financial Officer, Treasurer and Secretary of RespireRx Pharmaceuticals Inc., can be reached at 917-834-7206 or via email at jmargolis@respirerx.com, jmargolis@endeavourrx.com, and jmargolis@resolutionrx.com.au.
Source: RespireRx Pharmaceuticals Inc.
